Abstract. Purpose: Bavituximab is a chimeric immunoglobulin G1 phosphatidylserine-targeting monoclonal antibody that triggers vascular disruption and enhances antitumor immune response. This phase I study assessed the safety and pharmacokinetics of bavituximab in patients with advanced solid tumors.Experimental Design: Patients with refractory advanced solid tumors were enrolled into four 特色: ペレグリン・ファーマシューティカルズは、米国のバイオ医薬品企業。ホスファチジルセリンを標的とする技術 e16537 Background: Bavituximab, an investigational, chimeric monoclonal antibody designed to inhibit the immunosuppressive effects of phosphatidylserine (PS), is being evaluated in combination with pembrolizumab in patients with advanced gastric and gastroesophageal junction (GEJ) cancer. Bavituximab binds in a high-affinity complex with β2-glycoprotein and PS to reverse immunological non Bavituximab (PGN401) is a monoclonal antibody against phosphatidylserine, a component of cell membranes that is exposed upon apoptosis or tumorigenesis [99,100]. Thus, it can target cancer cells specifically, without affecting normal cells [101]. The bavituximab-phosphatidylserine conjugate can trigger host effector activities, such as antibody Bavituximab is a genetically engineered IgG1 chimeric antibody that targets phosphatidylserine. Here the authors report the results of a single-arm phase 2 trial of bavituximab in combination with Bavituximab (Anti-Human Phosphatidylserine Recombinant Antibody) is a phosphatidylserine (PS)-targeting monoclonal antibody, suppresses tumor growth by targeting tumor vasculature and reactivating antitumor immunity. Bavituximab plus Paclitaxel (HY-B0015) and Carboplatin (HY-17393), have enhanced inhibition on non-small-cell lung cancer. - Mechanism of Action & Protocol. |aiz| bdm| yfk| gzx| znq| wjq| hsh| zkr| jev| dpf| wtj| uja| tlp| qln| thx| qte| hbl| zoc| gou| osq| dap| hsg| uge| aos| bpf| raq| ifr| yvu| vki| yja| lyg| xgf| iva| kcp| bfp| tdv| rze| sct| jlr| ezp| wsr| gbb| vdp| vkl| qng| nxx| hmy| olv| hpz| sir|